Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $17.19
Previous CloseN/A
Volume2.95M
Average Volume (3M)990.46K
Market Cap
$107.22M
Enterprise ValueN/A
Total Cash (Recent Filing)$307.58M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
May 12, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding161,747,920
10 Day Avg. Volume775,248
30 Day Avg. Volume990,458
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.67Price Target Upside759.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Operational ImprovementsNeumora has made several operational changes to improve the probability of success for their KOASTAL-2 and -3 studies.
Pipeline PotentialNeumora is not just focused on a single product, and other innovative pipeline assets like the V1aR antagonist and M4 programs can also create meaningful shareholder value.
Bears Say
Market CompetitionRest of the pipeline still requires clinical validation, with concerns about being late to market compared to competitors.
Product DiscontinuationThe discontinuation of the phase 2 study evaluating nava for bipolar depression removes value from the company's model.
Stock PerformanceNMRA stock has significantly underperformed, with a drop of 86%, following negative Phase 3 study data for navacaprant.
---
Ownership Overview
25.49% Insiders
9.59% Mutual Funds
0.12% Other Institutional Investors
59.40% Public Companies and
Individual Investors
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.62 and its highest was $17.19 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $107.22M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is May 12, 2025 which is yesterday.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,747,920 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
---
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.67 (759.09% Upside)
$5.67 (759.09% Upside)
Blogger Sentiment
Neutral
NMRA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 116.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.22%
12-Months-Change
Fundamentals
Return on Equity
-64.48%
Trailing 12-Months
Asset Growth
-36.12%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
---
NMRA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company in transition, with strong financials and leadership changes poised to drive future growth. However, setbacks in the KOASTAL-1 study and the discontinuation of bipolar depression trials pose significant challenges. The overall sentiment is balanced between optimism for future potential and caution due to current setbacks.Read More>---
NMRA Stock 12 Month Forecast
Average Price Target
$5.67
▲(759.09% Upside)
Technical Analysis
---